June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Parapapillary Delta Zone as Risk Factor for Glaucoma in High Myopia
Author Affiliations & Notes
  • Jost B Jonas
    Ophthalmology, Medical Faculty Mannheim-Heidelberg, Mannheim, Germany
  • Kyoko Ohno-Matsui
    Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • Natsuko Nagaoka
    Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan
  • Pascal Weber
    Ophthalmology, Medical Faculty Mannheim-Heidelberg, Mannheim, Germany
  • Footnotes
    Commercial Relationships   Jost Jonas, Biocompatibles UK Ltd. (Franham, Surrey, UK) itle: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: : 20120263794 (P), Mundipharma Co (C), patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4). (P); Kyoko Ohno-Matsui, None; Natsuko Nagaoka, None; Pascal Weber, None
  • Footnotes
    Support  Supported by grants from the Japanese Society for Promotion of Science (number; 15H04993, 15K15629). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5491. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jost B Jonas, Kyoko Ohno-Matsui, Natsuko Nagaoka, Pascal Weber; Parapapillary Delta Zone as Risk Factor for Glaucoma in High Myopia. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5491.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine the prevalence and associated factors of glaucomatous optic neuropathy (GON) in a medium myopic to highly myopic patients.

Methods : The retrospective observational hospital-based study included patients who had attended the Tokyo High Myopia Clinics within January 2012 and December 2012 and for whom fundus photographs were available. GON was defined based on the appearance of the optic nerve head on the fundus photographs

Results : The study included 519 eyes (262 individuals) with a mean age of 62.0±14.3 years (range:13-89 years) and mean axial length of 29.5±2.2 mm (range:23.2-35.3mm). GON was present in 164 (28.1%; 95% confidence intervals (CI):24.4,31.7%) eyes. GON prevalence increased from 12.2% (95%CI:1.7,22.7) in eyes with an axial length of <26.5mm to 28.5% (24.4,32.5), 32.6% (27.9,37.2), 35.6% (30.5,41.1), and 42.1% (35.5,48.8) in eyes with an axial length of ≥26.5mm, ≥28mm, ≥29mm and ≥ 29mm, respectively. In multivariate analysis, higher GON prevalence was associated (Nagelkerke r2: 0.28) with larger parapapillary delta zone diameter (P<0.001; odds ratio (OR):1.86;95%CI:1.33,2.61), longer axial length (P<0.001;OR:1.45;95%CI:1.26,1.67) and older age (P=0.01;OR:1.03;95%CI:1.01,1.05). If parapapillary delta zone width was replaced by vertical disc diameter, higher GON prevalence was associated (r2:0.24) with larger vertical optic disc diameter (P=0.04;OR:1.70;95%CI:1.03,2.81), after adjusting for longer axial length (P<0.001;OR:1.44;95%CI:1.26,1.64) and older age (P<0.001;OR:1.04;95%CI:1.02,1.06).

Conclusions : Axial elongation associated increase in GON prevalence (mean: 28.1% in a medium to highly myopic study population) was associated with parapapillary delta zone as surrogate for an elongated peripapillary scleral flange and with larger optic disc size.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×